- Home
- ENB vs RVPHW Comparison
ENB vs RVPHW Comparison
Compare ENB & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENB
- RVPHW
- Stock Information
- Founded
- ENB 1949
- RVPHW 2018
- Country
- ENB Canada
- RVPHW United States
- Employees
- ENB N/A
- RVPHW 15
- Industry
- ENB Natural Gas Distribution
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- ENB Energy
- RVPHW Health Care
- Exchange
- ENB Nasdaq
- RVPHW Nasdaq
- Market Cap
- ENB N/A
- RVPHW N/A
- IPO Year
- ENB N/A
- RVPHW N/A
- Fundamental
- Price
- ENB $46.19
- RVPHW $0.06
- Analyst Decision
- ENB Buy
- RVPHW
- Analyst Count
- ENB 1
- RVPHW 0
- Target Price
- ENB $67.00
- RVPHW N/A
- AVG Volume (30 Days)
- ENB 4.5M
- RVPHW 22.4K
- Earning Date
- ENB 05-09-2025
- RVPHW 03-14-2025
- Dividend Yield
- ENB 5.75%
- RVPHW N/A
- EPS Growth
- ENB N/A
- RVPHW N/A
- EPS
- ENB 1.63
- RVPHW N/A
- Revenue
- ENB $37,163,965,415.00
- RVPHW N/A
- Revenue This Year
- ENB $0.24
- RVPHW N/A
- Revenue Next Year
- ENB $2.97
- RVPHW N/A
- P/E Ratio
- ENB $28.40
- RVPHW N/A
- Revenue Growth
- ENB 22.51
- RVPHW N/A
- 52 Week Low
- ENB $34.60
- RVPHW $0.13
- 52 Week High
- ENB $46.47
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- ENB 64.31
- RVPHW N/A
- Support Level
- ENB $44.63
- RVPHW N/A
- Resistance Level
- ENB $46.01
- RVPHW N/A
- Average True Range (ATR)
- ENB 1.26
- RVPHW 0.00
- MACD
- ENB 0.29
- RVPHW 0.00
- Stochastic Oscillator
- ENB 95.85
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.